Incidence Of Uropathogenic Candida Strains In Urinary Tract Infections

1.1 Background to the Study

Urinary tract infections (UTIs) are among the most common infections globally, affecting an estimated 150 million people annually and contributing significantly to healthcare-related morbidity and costs (Flores-Mireles et al., 2019). While Escherichia coli remains the leading bacterial cause of UTIs, the landscape of uropathogens is shifting. There is increasing recognition of fungal infections, particularly those caused by Candida species, as emerging and often underestimated agents of urinary tract infections, particularly in vulnerable populations such as immunocompromised individuals, elderly patients, and those with prolonged hospitalizations or indwelling urinary catheters (Lo et al., 2024).

Candiduria, defined as the presence of Candida species in the urine, has become a frequently encountered clinical challenge, particularly in hospital settings. Although traditionally regarded as a benign colonizer, Candida is now recognized as a potential uropathogen, especially in patients with risk factors such as diabetes, immunosuppressive therapy, and urinary tract abnormalities (Montoya & Mody, 2021). Notably, Candida albicans, Candida glabrata, and Candida tropicalis were historically the primary species involved in candiduria. However, in recent years, Candida auris has emerged as a notable and concerning uropathogen, particularly in healthcare settings.

The emergence of Candida auris represents a significant public health concern due to its multidrug resistance, high mortality rate, and ability to cause hospital outbreaks (Lionakis & Chowdhary, 2024). First identified in 2009, C. auris has since spread globally, causing invasive infections including bloodstream infections, wound infections, and UTIs. Its tendency to colonize the skin and persist in healthcare environments poses a serious threat to infection control (Centers for Disease Control and Prevention, 2024). Moreover, C. auris has demonstrated the ability to form robust biofilms on medical devices, including urinary catheters, complicating eradication efforts and increasing the risk of catheter-associated urinary tract infections (CAUTIs) (La Bella et al., 2023).

CAUTIs represent a substantial proportion of healthcare-associated infections (HAIs) and are often complicated by the presence of multidrug-resistant organisms (Rosenthal et al., 2024). Patients with indwelling urinary catheters for prolonged periods are at particularly high risk, as these devices provide a direct pathway for pathogens and an environment conducive to biofilm development (Czwikla et al., 2023). Biofilms protect microbial communities from the host immune system and antifungal agents, making infections difficult to treat. Studies have shown that Candida biofilms are associated with increased resistance to azoles and echinocandins, the major classes of antifungal medications (Spruijtenburg et al., 2023).

Despite its rising clinical importance, candiduria is often underdiagnosed or dismissed as contamination, leading to inadequate treatment and potential complications such as pyelonephritis, fungemia, and urosepsis (Wagenlehner et al., 2023). This is particularly concerning in long-term care facilities and nursing homes, where elderly and debilitated patients frequently have catheters and multiple comorbidities (Rogers et al., 2022). In these environments, the prevalence of candiduria is high, yet systematic screening and management strategies are often lacking (Advani et al., 2024).

Furthermore, the global burden of C. auris is compounded by its ability to cause outbreaks in both high- and low-resource settings. For instance, outbreaks have been reported in Brazil, Saudi Arabia, India, and the United Arab Emirates, with varying degrees of morbidity and mortality (Alagha et al., 2024; de Melo et al., 2023; Alshahrani et al., 2023; Thomsen et al., 2024). In many cases, delayed diagnosis and limited antifungal options contributed to poor outcomes. C. auris often exhibits resistance to fluconazole and variable susceptibility to other antifungals, necessitating susceptibility testing for appropriate treatment selection (Tajane et al., 2024). The global nature of its spread underscores the need for standardized surveillance, reporting, and infection control practices.

Healthcare settings must adopt comprehensive strategies to prevent and manage CAUTIs, particularly those caused by fungal pathogens. The 2014 update by the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America recommended several evidence-based interventions, including minimizing catheter use, employing aseptic insertion techniques, and promoting early catheter removal (Lo et al., 2024). However, these strategies have primarily targeted bacterial infections and often neglect the unique challenges posed by fungal organisms. The presence of fungal biofilms and multidrug resistance necessitates the development of new antifungal agents, alternative therapies, and enhanced diagnostic techniques.

The diagnostic challenges surrounding candiduria and CAUTIs are notable. Unlike bacterial UTIs, the presence of Candida in urine does not always correlate with clinical symptoms, particularly in asymptomatic patients (European Centre for Disease Prevention and Control, 2018). Distinguishing colonization from infection remains difficult without invasive diagnostics. This has led to considerable debate about when and how to treat candiduria, especially in patients without systemic signs of infection. Nevertheless, in high-risk populations, such as those undergoing urological procedures, prompt identification and treatment may be warranted (Biagi et al., 2019).

In addition to clinical and microbiological challenges, there are important public health implications of rising candiduria and CAUTI rates due to C. auris. Studies have demonstrated that C. auris can persist in hospital environments and contaminate surfaces, equipment, and healthcare workers’ hands, leading to nosocomial transmission (Allaw et al., 2021). This necessitates strict adherence to environmental cleaning protocols, contact precautions, and hand hygiene practices to contain its spread.

Molecular studies have further revealed the clonal nature of C. auris outbreaks, with specific genetic lineages dominating in certain geographical regions (Alfouzan et al., 2020). Whole genome sequencing has also uncovered mutations that confer resistance to echinocandins, raising concerns about future treatment options (Spruijtenburg et al., 2023). As resistance continues to evolve, healthcare institutions must invest in antimicrobial stewardship programs and explore innovative treatment strategies, including combination therapies and novel antifungals.

Moreover, the COVID-19 pandemic exacerbated the spread of C. auris, as overwhelmed healthcare systems struggled with infection prevention and control measures. In Lebanon, the first outbreak of C. auris was reported during the pandemic, highlighting the vulnerability of healthcare infrastructures during times of crisis (Allaw et al., 2021). This underscores the importance of sustained vigilance, robust surveillance systems, and research funding to address emerging fungal threats.

1.2 Statement of the Problem

Catheter-associated urinary tract infections (CAUTIs) represent one of the most common and persistent healthcare-associated infections, particularly within nursing home and hospital environments. Despite decades of surveillance and intervention strategies, their prevalence remains high, and the complications associated with CAUTIs—such as urosepsis, candidemia, and antimicrobial resistance—continue to challenge healthcare systems globally (Flores-Mireles et al., 2019; Lo et al., 2024). Although various guidelines have been established to prevent CAUTIs in acute care settings, many fail to translate effectively into long-term care practices and nursing homes (Montoya & Mody, 2021). Furthermore, the presence of indwelling catheters remains significantly underreported and poorly managed in such settings (Czwikla et al., 2023).

A notable gap in the existing body of literature is the limited integration of microbiological surveillance and device management protocols within routine nursing care, especially in resource-limited environments. While Rosenthal et al. (2024) provided valuable insight into CAUTI incidence across multiple international settings, there is inadequate focus on the behavioral and institutional factors that hinder effective prevention at the ward level. Moreover, emerging fungal infections like Candida auris, often associated with catheter use, add an additional layer of complexity due to their resistance and high mortality (Tajane et al., 2024; Alagha et al., 2024). However, little is known about how nurses are trained or supported to identify and mitigate such risks during catheter care.

Additionally, the evolving nature of infection metrics—as noted by Advani et al. (2024)—demands a paradigm shift in surveillance that goes beyond device-associated infections to encompass broader patient-centered outcomes. This suggests a critical need for empirical studies focusing on nursing roles, institutional support, and infection-specific education in catheter management. Therefore, this study aims to bridge these gaps by investigating the underexplored interplay between nursing practices, organizational factors, and CAUTI prevention outcomes.

1.3 Objectives of the Study

The general objective of this study is to investigate the incidence of uropathogenic Candida strains in urinary tract infections. The specific objectives are to:

1. Determine the prevalence of Candida species among patients diagnosed with urinary tract infections.

2. Identify and characterize the specific Candida species implicated in urinary tract infections.

3. Evaluate the antifungal susceptibility patterns of Candida isolates from urinary specimens.

1.4 Research Questions

This study aims to provide answers to the following research questions:

1. What is the prevalence of Candida species in urinary tract infections among patients in the study area?

2. Which Candida species are most commonly associated with urinary tract infections?

3. What are the antifungal susceptibility patterns of Candida species isolated from urine samples?

1.5 Research Hypotheses

To guide the study, the following null hypotheses were formulated:

1. H0: There is no significant prevalence of Candida species among patients with urinary tract infections.

2. H0: There is no significant variation in the distribution of Candida species involved in urinary tract infections.

3. H0: There is no significant resistance of uropathogenic Candida species to commonly used antifungal agents.

1.6 Significance of the Study

This study holds significant value across several critical dimensions. It addresses a notable gap in the existing literature on fungal urinary tract infections, which are frequently overlooked and insufficiently investigated, especially in low- and middle-income countries. The research aims to determine the incidence and spread of Candida species responsible for urinary tract infections. By doing so, it has the potential to improve the accuracy and timeliness of diagnoses, which is essential for reducing the morbidity associated with misidentified or untreated infections. Accurate identification of the specific Candida strains involved can also guide the selection of more effective antifungal treatments, thereby lowering the risk of treatment failure and reducing the emergence of drug-resistant fungal strains.

The study also serves to inform and enhance clinical practice. Healthcare professionals, such as clinicians, microbiologists, and infection control experts, can benefit from the data generated by this research. By adopting evidence-based strategies grounded in the study’s findings, they can more effectively manage patients presenting with symptoms of candiduria. This includes choosing the most appropriate diagnostic methods, implementing targeted treatment protocols, and improving patient monitoring procedures. The practical insights derived from the study will help ensure better clinical outcomes for patients suffering from fungal urinary infections.

Beyond the clinical setting, the study has implications for public health policy. Policymakers can use the findings to establish or refine guidelines for routine screening, diagnosis, and reporting of Candida infections of the urinary tract. This is especially critical for vulnerable groups, such as elderly individuals, diabetic patients, and those with long-term catheterization, who are at increased risk of developing these infections. By informing surveillance strategies and shaping infection control policies, the study contributes to a more responsive and proactive healthcare system.

1.7 Scope of the Study

This study is limited to patients presenting with symptoms of urinary tract infections at selected healthcare facilities within the defined study area. It focuses exclusively on the isolation, identification, and characterization of Candida species from urine specimens. Bacterial uropathogens and non-urinary fungal infections are excluded from the scope. The study also evaluates the antifungal susceptibility patterns of isolated Candida strains to commonly used antifungal agents. Demographic data such as age, sex, and underlying medical conditions will also be considered to determine risk factors associated with candiduria. The study will span a period of six months, and samples will be collected following ethical guidelines and patient consent.

1.8 Operational Definition of Key Terms

Uropathogenic: Refers to microorganisms, particularly pathogens, capable of causing disease in the urinary tract.

Candida species: A genus of yeasts that includes several species, some of which can cause infections in humans, particularly in immunocompromised individuals.

Candiduria: The presence of Candida species in the urine, which may be indicative of colonization or a urinary tract infection.

Urinary Tract Infection (UTI): An infection that occurs in any part of the urinary system, including the kidneys, ureters, bladder, and urethra, typically caused by pathogens.

Antifungal Susceptibility: The sensitivity or resistance of fungal organisms to antifungal medications, usually determined through laboratory testing.

Biofilm Formation: A survival mechanism in which microorganisms adhere to surfaces and produce a protective matrix, often contributing to persistent infections.

Nosocomial Infection: An infection acquired in a hospital setting, often involving resistant pathogens due to extensive use of antimicrobial agents.

Immunocompromised: Describes individuals whose immune system is weakened or suppressed, making them more vulnerable to infections, including fungal UTIs.